This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/07/2023 04:00 PM

# **BUY** Mahindra & Mahindra

# Muted Q2; valuations still reasonable

Auto & Auto Ancillaries > Result Update > November 13, 2023

M&M's Q2 results were marked by sequential margin weakness (down by 138bps to 12.1%), on increase in costs across line items, though PAT beat our estimates due to higher other income. For M&M, valuations remain supportive (~14x core FY26E PER) amid reasonably-healthy automotive demand prospects (we build-in ~10% volume CAGR over FY23-26E), though Farm segment demand is expected to be relatively muted (we factor-in ~4% volume CAGR), given the high base. We upgrade FY24E EPS by ~9%, largely to reflect higher than expected other income in H1; FY25E/FY26E EPS is revised upwards marginally by ~1% each. We maintain BUY on M&M, given the undemanding valuations with revised SOTP-based TP of Rs1,690/share (Rs1,590 earlier; including ~Rs460/share for subsidiaries/investments; rolled over to FY26E).

Mahindra & Mahindra: Financial Snapshot (Standalone)								
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E			
Revenue	5,77,869	8,49,603	10,15,158	11,00,509	11,68,650			
EBITDA	70,275	1,03,795	1,29,849	1,40,096	1,51,693			
Adj. PAT	50,786	79,782	1,02,459	1,00,518	1,08,702			
Adj. EPS (Rs)	40.9	64.2	82.4	80.9	87.4			
EBITDA margin (%)	12.2	12.2	12.8	12.7	13.0			
EBITDA growth (%)	1.0	47.7	25.1	7.9	8.3			
Adj. EPS growth (%)	394.8	34.5	56.5	(1.9)	8.1			
RoE (%)	13.9	19.6	21.7	18.3	17.3			
RoIC (%)	29.7	41.0	53.4	61.4	62.2			
P/E (x)	37.7	24.0	18.7	19.1	17.6			
EV/EBITDA (x)	26.6	17.6	13.8	12.3	10.9			
P/B (x)	5.0	4.4	3.8	3.3	2.9			
FCFF yield (%)	2.0	3.8	3.9	5.8	5.9			

Source: Company, Emkay Research

### Subdued margin performance sequentially

Revenue rose ~16% YoY to Rs243bn (below estimates), amid ~11% YoY volume growth and ~1% QoQ growth in realizations. EBITDA increased 20% YoY to Rs29.3bn, with EBITDA margin down by 138bps QoQ to 12.1% (Consensus/Emkay est.: 12.9%/13.3%); the miss was owing to higher than expected costs across line items. Gross margins dipped by ~30bps QoQ. Auto segment revenue grew 22% YoY to Rs184bn, while Farm segment revenue was flattish YoY at Rs59bn. EBIT margin for the Auto segment rose by 150bps QoQ, at 9% (underlying Auto margins, however, were up by ~40bps, at 7.9%), while Farm segment EBIT margin declined by 149bps QoQ, to 16%. Adjusted PAT grew 49% YoY to Rs34.5bn (above estimates), driven by higher than expected other income.

### **Earnings call KTAs**

1) In Automotive, demand for the above-Rs1.3-1.4mn/unit segment remains strong, while that for the sub-Rs1-1.2mn/unit segment remains weak; M&M's automotive orderbook saw marginal growth to 286K units (vs. 281K units in Q1/290K units in Apr-23); channel inventory as of Q2 is at ~30 days, in line with the industry; cancellation rates remain below 8%. 2) Tractor industry volumes expected to be flattish in FY24, with Mar-24 volumes seen declining due to an adverse base effect (Navratras-induced strong Mar-23). 3) The Automotive segment has reported healthy double-digit growth in the first 20 days of the festive period; Tractors saw some growth during the first few days of Navratras, along expected lines. 4) Remains on track to reach 49K/month automotive capacity run-rate by Mar-24; capacity beyond this would be augmented for upcoming Thar 5-door and the born electric portfolio; would continue investing in ICE, though the lesser age of most of the current portfolio would enable some savings in outlay for a pipeline refresh over the next few years; most manufacturing facilities for ICE and EVs to be fungible. 5) Company has ~60% market share in L5 category E-3Ws and sees robust growth prospects (amid  $\sim 10\%$  penetration); margins for the category need to be similar to those of ICE in the longer run, to be able to compete. 6) Retains 18% RoE target (achieved ~20% in H1).



### **TARGET PRICE (Rs): 1,690**

Target Price – 12M	Sep-24
Change in TP (%)	6.3
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	9.7
CMP (13-Nov-23) (Rs)	1,541.0
Stock Data	Ticker
52-week High (Rs)	1,670
52-week Low (Rs)	1,123
Shares outstanding (mn)	1,243.5
Market-cap (Rs bn)	1,916
Market-cap (USD mn)	22,996
Net-debt, FY24E (Rs mn)	-1,29,580
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	3,821.9
ADTV-3M (USD mn)	45.9
Free float (%)	76.9
Nifty-50	19,444
INR/USD	83.3
Shareholding, Sep-23	
Promoters (%)	18.9
FPIs/MFs (%)	39.3/26.2

Price Performance							
(%)	1M	ЗМ	12M				
Absolute	(1.4)	(0.4)	19.7				
Rel. to Nifty	0.2	(0.4)	13.0				



#### Chirag Jain

chirag.jain@emkayglobal.com +91 22 6624 2428

#### Jaimin Desai

jaimin.desai@emkayglobal.com +91 22 6612 1334

### Vijay Naraharisetty

vijay.naraharisetty@emkayglobal.com +91 22 6612 1306

I his report is intended for feam.emkay@whitemarquesolutions.com use and downloaded at 12/07/2023 04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Mahindra & Mahindra (MM IN)

000 (%)

Ē	Exhibit 1: Q2FY24 snapshot – S	Sequential marg	jin performance	impacted by inc	rease in costs u	nder all line iten	າຣ
	(Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)

(KS IIII)	201123	3QF123	401123	106124	201124	101 (%)	QUQ (%)
Revenue	2,10,101	2,16,537	2,25,714	2,40,561	2,43,099	15.7	1.1
Expenditure	1,85,667	1,88,395	1,97,831	2,08,209	2,13,758	15.1	2.7
as % of sales	88.4	87.0	87.6	86.6	87.9		
Consumption of RM	1,60,768	1,64,471	1,69,219	1,81,149	1,83,793	14.3	1.5
as % of sales	76.5	76.0	75.0	75.3	75.6		
Employee Cost	9,224	9,342	9,490	10,447	11,262	22.1	7.8
as % of sales	4.4	4.3	4.2	4.3	4.6		
Other expenditure	15,675	14,583	19,121	16,613	18,703	19.3	12.6
as % of sales	7.5	6.7	8.5	6.9	7.7		
EBITDA	24,434	28,142	27,883	32,351	29,341	20.1	(9.3)
Depreciation	7,913	8,292	8,385	8,281	8,158	28.2	(1.5)
EBIT	16,521	19,851	19,498	24,070	21,182	28.2	(12.0)
Other Income	13,673	6,700	3,429	9,699	22,819	66.9	135.3
Interest	641	686	698	323	329	(48.7)	1.8
PBT	29,553	25,865	22,229	33,445	43,672	47.8	30.6
Total Tax	6,394	5,575	1,621	5,708	9,153	43.2	60.4
Adjusted PAT	23,159	20,290	20,608	27,737	34,519	49.1	24.4
Extra ordinary items	(2,479)	(5,009)	(5,118)	-	-		
Reported PAT	20,680	15,281	15,490	27,737	34,519	66.9	24.4
(%)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (bps)	QoQ (bps)
EBITDAM	11.6	13.0	12.4	13.4	12.1	44	-138
EBITM	7.9	9.2	8.6	10.0	8.7	85	-129
EBTM	14.1	11.9	9.8	13.9	18.0	390	406
PATM	11.0	9.4	9.1	11.5	14.2	318	267

Effective Tax rate

21.6

21.6

Source: Company, Emkay Research

# Exhibit 2: Actual vs estimates

Rs mn	Actual	Emkay Est	Var %	Consensus	Var %
Net sales	2,43,099	2,48,789	(2.3)	2,46,681	(1.5)
EBITDA	29,341	33,089	(11.3)	31,776	(7.7)
EBITDA Margin (%)	12.1	13.3	(123) bps	12.9	(81) bps
Adj net income	34,519	28,028	23.2	28,116	22.8
EPS (Rs)	27.8	22.5	23.2	22.6	22.8

7.3

17.1

21.0

-68

389

Source: Company, Emkay Research

Exhibit 3: Segmental performance	- Underlying Auto EBIT up b	y ~40bps QoQ to 7.9%;	Tractor EBIT margin down by 150bps
----------------------------------	-----------------------------	-----------------------	------------------------------------

Segmental details (Rs mn)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	YoY (%)	QoQ (%)
Farm Equipment							
Tractor (Units)	93,540	1,05,765	89,731	1,15,009	90,061	(3.7)	(21.7)
Net Sales (Rs mn)	59,446	62,777	60,117	74,556	59,195	(0.4)	(20.6)
Avg realizations	6,35,518	5,93,549	6,69,969	6,48,263	6,57,277	3.4	1.4
EBIT (Rs mn)	9,691	10,393	9,848	13,027	9,464	(2.3)	(27.4)
EBIT margin (%)	16.3	16.6	16.4	17.5	16.0	(32) bps	(149) bps
Automotive (incl. MVML)							
Auto (units)	1,79,683	1,76,094	1,89,227	1,86,138	2,12,078	18.0	13.9
Net Sales (Rs mn)	1,50,893	1,47,965	1,65,876	1,66,210	1,84,055	22.0	10.7
Avg realizations (Rs)	8,39,773	8,40,263	8,76,600	8,92,940	8,67,863	3.3	(2.8)
EBIT (Rs mn)	8,831	9,896	11,761	12,524	16,624	88.2	32.7
Margins (%)	5.9	6.7	7.1	7.5	9.0	318 bps	150 bps

Source: Company, Emkay Research

This report is intended for team emkay @whitemarguesolutions com use and downloaded at 12/07/2023 04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 4: Revenue model - We build-in 11%/13% CAGR in revenue/core EPS, over FY23-26E

(Rs mn)	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Volumes (units)	7,73,094	7,03,119	8,20,299	11,06,001	12,34,353	13,22,726	13,90,071
Growth (%)	-17.6	-9.1	16.7	34.8	11.6	7.2	5.1
Segmental volumes							
Automotive	4,71,179	3,48,621	4,65,601	6,98,456	8,20,818	8,88,029	9,33,288
Growth (%)	(22)	(26)	34	50	18	8	5
SUVs	1,89,758	1,61,457	2,33,400	3,67,474	4,64,385	5,13,760	5,47,730
Growth (%)	(23)	(15)	45	57	26	11	7
Tractors	3,01,915	3,54,498	3,54,698	4,07,545	4,13,534	4,34,697	4,56,782
Growth (%)	(9)	17	0	15	1	5	5
<u>Volume mix (%)</u>							
Automotive	61	50	57	63	66	67	67
Tractors	39	50	43	37	34	33	33
ASP (Rs/unit)	5,80,337	6,34,741	7,04,462	7,68,175	8,22,421	8,32,001	8,40,712
Growth (%)	3	9	11	9	7	1	1
Revenue	4,48,655	4,46,299	5,77,869	8,49,603	10,15,158	11,00,509	11,68,650
Growth (%)	(15.1)	(0.5)	29.5	47.0	19.5	8.4	6.2
Revenue mix (%)							
Automotive	61.6	54.8	61.9	67.8	70.6	71.2	71.2
Tractors	34.1	41.1	34.1	29.4	26.7	26.2	26.2
EBITDA	63,506	69,575	70,275	1,03,795	1,29,849	1,40,096	1,51,693
EBITDA margin (%)	14.2	15.6	12.2	12.2	12.8	12.7	13.0
EBITDA growth (%)	(15.7)	9.6	1.0	47.7	25.1	7.9	8.3
EBITDA/vehicle (%)	82,145	98,952	85,670	93,847	1,05,196	1,05,915	1,09,126
EBIT	42,226	48,214	48,319	76,702	1,01,923	1,10,100	1,19,906
EBIT margin (%)	9.4	10.8	8.4	9.0	10.0	10.0	10.3
Segmental margins (%)							
Automotive	6.1	3.4	3.6	4.8	7.9	8.5	9.0
Tractors	19.0	22.7	18.1	16.2	17.5	17.5	17.7
<u>EBIT mix (%)</u>							
Automotive	35.9	16.5	25.6	36.1	53.4	55.9	57.0
Tractors	62.5	83.0	71.7	53.4	44.8	42.3	41.2
Core EPS (excl. dividend income; Rs)	20.5	28.2	29.9	51.2	69.5	67.9	74.5

Source: Company, Emkay Research

### Exhibit 5: We raise FY24E EPS by ~9%, largely tracking higher other income; FY25E/FY26E EPS revised marginally upwards

Down		FY2	4E			FY2	5E			FY26E			
Rs mn	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	
Volume (units)	12,16,978	12,34,353	1.4	11.6	12,86,953	13,22,726	2.8	7.2	13,55,371	13,90,071	2.6	5.1	
Revenue	9,97,257	10,15,158	1.8	19.5	10,66,242	11,00,509	3.2	8.4	11,36,076	11,68,650	2.9	6.2	
EBITDA	1,29,744	1,29,849	0.1	25.1	1,38,694	1,40,096	1.0	7.9	1,50,076	1,51,693	1.1	8.3	
EBITDA margin (%)	13.0	12.8	(22) bps	57 bps	13.0	12.7	(28) bps	(6) bps	13.2	13.0	(23) bps	25 bps	
Adj. PAT	93,667	1,02,459	9.4	28.4	99,206	1,00,518	1.3	(1.9)	1,07,229	1,08,702	1.4	8.1	
EPS (Rs)	75.3	82.4	9.4	28.4	79.8	80.9	1.3	(1.9)	86.3	87.4	1.4	8.1	

Source: Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 12/07/2023.04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 6: SOTP-based TP of Rs1,690/share

Components (Rs bn)	Basis of Valuation	Equity value	M&M stake (%)	Pro- rata value	Hold-co discount (%)	Contr. To SOTP	SOTP (Rs/share)	SOTP breakdown (%)
Tractor division	DCF	476		476		476	383	23
CV and 3W divisions	DCF	413		413		413	332	20
PV-ICE division	DCF	312		312		312	251	15
PV-EV division	50% discount to Transaction value	324		324		324	261	15
Standalone business		1,201		1,201		1,201	1,227	57
Tech Mahindra	TP (Emkay)	1,296	25.5	330	20	264	212	13
M&M Financial Services	TP (Emkay)	290	52.2	151	20	121	97	6
Other Subs/investments	Current m-cap/ investment value					190	153	9
Total						2,100	1,689	100
Total (Rounded off)							1,690	

Source: Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 12/07/2023.04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Mahindra & Mahindra: Standalone Financials and Valuations

India Equity	Research	Result	Update

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	5,77,869	8,49,603	10,15,158	11,00,509	11,68,650
Revenue growth (%)	29.5	47.0	19.5	8.4	6.2
EBITDA	70,275	1,03,795	1,29,849	1,40,096	1,51,693
EBITDA growth (%)	1.0	47.7	25.1	7.9	8.3
Depreciation & Amortization	24,984	31,545	33,245	35,763	37,653
EBIT	45,291	72,250	96,604	1,04,333	1,14,040
EBIT growth (%)	(1.3)	59.5	33.7	8.0	9.3
Other operating income	0	0	0	0	0
Other income	20,538	26,081	37,951	27,704	28,455
Financial expense	2,262	2,728	2,349	2,337	2,234
РВТ	63,567	95,603	1,32,205	1,29,700	1,40,261
Extraordinary items	(2,087)	(14,295)	0	0	0
Taxes	12,781	15,821	29,746	29,183	31,559
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	48,699	65,486	1,02,459	1,00,518	1,08,702
PAT growth (%)	394.8	34.5	56.5	(1.9)	8.1
Adjusted PAT	50,786	79,782	1,02,459	1,00,518	1,08,702
Diluted EPS (Rs)	40.9	64.2	82.4	80.9	87.4
Diluted EPS growth (%)	394.8	34.5	56.5	(1.9)	8.1
DPS (Rs)	11.1	15.9	20.6	20.2	21.9
Dividend payout (%)	28.4	30.2	25.0	25.0	25.0
EBITDA margin (%)	12.2	12.2	12.8	12.7	13.0
EBIT margin (%)	7.8	8.5	9.5	9.5	9.8
Effective tax rate (%)	20.1	16.5	22.5	22.5	22.5
NOPLAT (pre-IndAS)	36,184	60,293	74,868	80,858	88,381
Shares outstanding (mn)	1,243.2	1,243.2	1,243.2	1,243.2	1,243.2

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	5,983	5,991	5,991	5,991	5,991
Reserves & Surplus	3,75,998	4,27,577	5,04,421	5,79,809	6,61,336
Net worth	3,81,981	4,33,567	5,10,411	5,85,800	6,67,326
Minority interests	0	0	0	0	C
Deferred tax liability (net)	17,622	14,703	11,047	7,460	3,582
Total debt	70,585	50,255	54,164	54,532	54,422
Total liabilities & equity	4,70,187	4,98,525	5,75,622	6,47,792	7,25,330
Net tangible fixed assets	1,12,881	1,30,501	1,06,293	1,38,424	1,55,771
Net intangible assets	26,610	39,261	39,261	39,261	39,261
Net ROU assets	0	0	0	0	C
Capital WIP	52,627	27,846	83,809	70,916	70,916
Goodwill	0	0	0	0	C
Investments [JV/Associates]	1,63,024	1,75,391	1,82,891	1,90,391	1,97,891
Cash & equivalents	1,15,526	1,40,298	1,83,744	2,48,119	3,10,692
Current assets (ex-cash)	1,85,848	2,44,502	2,92,375	3,16,957	3,36,582
Current Liab. & Prov.	1,95,878	2,59,273	3,12,750	3,56,274	3,85,781
NWC (ex-cash)	(10,030)	(14,771)	(20,375)	(39,318)	(49,199)
Total assets	4,70,187	4,98,525	5,75,622	6,47,792	7,25,330
Net debt	(44,941)	(90,042)	(1,29,580)	(1,93,587)	(2,56,270)
Capital employed	4,70,187	4,98,525	5,75,622	6,47,792	7,25,330
Invested capital	1,39,010	1,54,991	1,25,178	1,38,367	1,45,832
BVPS (Rs)	307.3	348.8	410.6	471.2	536.8
Net Debt/Equity (x)	(0.1)	(0.2)	(0.3)	(0.3)	(0.4)
Net Debt/EBITDA (x)	(0.6)	(0.9)	(1.0)	(1.4)	(1.7)
Interest coverage (x)	0.0	0.0	0.0	0.0	0.0
RoCE (%)	10.8	15.2	18.8	16.2	15.6

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	63,567	95,603	1,32,205	1,29,700	1,40,261
Others (non-cash items)	8,273	19,194	41,195	42,865	44,706
Taxes paid	(5,984)	(19,380)	(33,402)	(32,769)	(35,437)
Change in NWC	3,913	(4,125)	(5,842)	14,663	3,016
Operating cash flow	69,767	91,293	1,34,156	1,54,459	1,52,545
Capital expenditure	(32,916)	(21,597)	(65,000)	(55,000)	(55,000)
Acquisition of business	(23,968)	(32,350)	(50,000)	(65,000)	(65,000)
Interest & dividend income	17,248	2,747	0	0	0
Investing cash flow	Investing cash flow (39,636) (34,819) (1,15,000) (1,20,000) (1,20,000)				
Equity raised/(repaid)	33	8	0	0	0
Debt raised/(repaid)	(15,978)	(20,330)	3,908	368	(109)
Payment of lease liabilities	(497)	(1,138)	0	0	0
Interest paid	(4,824)	(2,728)	(2,349)	(2,337)	(2,234)
Dividend paid (incl tax)	(10,891)	(19,769)	(25,615)	(25,129)	(27,175)
Others	(25,421)	8,510	5,846	(485)	2,046
Financing cash flow	(57,578)	(35,446)	(18,210)	(27,584)	(27,472)
Net chg in Cash	(27,446)	21,028	946	6,875	5,073
OCF	69,767	91,293	1,34,156	1,54,459	1,52,545
Adj. OCF (w/o NWC chg.)	65,855	95,418	1,39,998	1,39,796	1,49,529
FCFF	36,852	69,696	69,156	99,459	97,545
FCFE	51,838	69,716	66,807	97,122	95,312
OCF/EBITDA (%)	99.3	88.0	103.3	110.3	100.6
FCFE/PAT (%)	106.4	106.5	65.2	96.6	87.7
FCFF/NOPLAT (%)	101.8	115.6	92.4	123.0	110.4

Source: Company, Emkay Research

Valuations and key Ra	tios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	37.7	24.0	18.7	19.1	17.6
P/CE(x)	25.3	17.2	14.1	14.1	13.1
P/B (x)	5.0	4.4	3.8	3.3	2.9
EV/Sales (x)	3.2	2.1	1.8	1.6	1.4
EV/EBITDA (x)	26.6	17.6	13.8	12.3	10.9
EV/EBIT(x)	41.3	25.3	18.5	16.5	14.6
EV/IC (x)	13.5	11.8	14.3	12.4	11.4
FCFF yield (%)	2.0	3.8	3.9	5.8	5.9
FCFE yield (%)	2.7	3.6	3.5	5.1	5.0
Dividend yield (%)	0.7	1.0	1.3	1.3	1.4
DuPont-RoE split					
Net profit margin (%)	8.8	9.4	10.1	9.1	9.3
Total asset turnover (x)	1.3	1.8	1.9	1.8	1.7
Assets/Equity (x)	1.3	1.2	1.1	1.1	1.1
RoE (%)	13.9	19.6	21.7	18.3	17.3
DuPont-RoIC					
NOPLAT margin (%)	6.3	7.1	7.4	7.3	7.6
IC turnover (x)	0.0	0.0	0.0	0.0	0.0
RoIC (%)	29.7	41.0	53.4	61.4	62.2
Operating metrics					
Core NWC days	(6.3)	(6.3)	(7.3)	(13.0)	(15.4)
Total NWC days	(6.3)	(6.3)	(7.3)	(13.0)	(15.4)
Fixed asset turnover	2.0	2.5	2.8	2.7	2.5
Opex-to-revenue (%)	14.2	11.8	11.9	12.5	12.2

Source: Company, Emkay Research

This report is intended for team emkay @ whitemarguesolutions.com use and downloaded at 12/07/2023\_04:00\_PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
05-Aug-23	1,465	1,590	Buy	Chirag Jain
26-May-23	1,282	1,500	Buy	Chirag Jain

## **RECOMMENDATION HISTORY - TREND**



Source: Company, Emkay Research

Source: Company. Bloomberg, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 12/07/2023.04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkavglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 12/07/2023 04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for gualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1 the securities recommended in this report as of November 13, 2023
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of November 13, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the November 13, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for 7 investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

## Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 12/07/2023 04:00 PM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.